Boehringer Ingelheim | Gold Partner
Boehringer Ingelheim has a 137-year history. Founded in 1885 by Albert Boehringer (1861-1939), it remains a family company.
Boehringer Ingelheim started its business in Greece in 1966. In 1973 Boehringer Ingelheim Hellas was founded, and in 1975 the opening of its factory in Koropi began. The subsidiary, like its parent, is owned by the Boehringer family and is not listed on the stock exchange.
The factory at Koropi is nowadays one of the most important factories of Boehringer Ingelheim GmbH for the production of medicines for Human Use. Boehringer Ingelheim implements industry 4.0 specification systems and functions as well as advanced production systems with AI protocols.
Boehringer Ingelheim is an export giant in Greece: Produces and packages innovative medicines to export them to more than 90 countries). In 2022 its export level reached 1,024 bio € (41% of the total exports of medicines, i.e 2,9% of overall Greek exports excluding petroleum). Y 2023 exports exceeded 1.2 billion €, which is estimated to be close to 3% of the country's total exports (amount of exports excluding mineral oils). After the completion of the investment plan (2023-2027) the new Group Medicines will be produced, and the Koropi plant will become even more important for the global network of the Company.
Boehringer Ingelheim Hellas is also responsible for the distribution (market authorization) of its innovative medicines in Cyprus. Furthermore, the company participates in the international clinical studies program of the parent company.
For all its activities Boehringer Ingelheim Hellas employs almost 700 employees. Its employees are among the leading scientists and professionals in the industry with the necessary skills, education, and experience to promote its vision of “Value through Innovation”.
According to Wifor international institute, one job of a Boehringer ingelheim employee supports 5,82 indirect Jobs for the Greek economy.
The company's vision is to provide value through innovation by putting the patient at the center of all its activities. By doing so Boehringer Ingelheim puts Life forward
Boehringer Ingelheim was appointed in 2015 one of the 100 most innovative companies in the world by the independent organization Thomson Reuters.
